Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine 6-monatige und 18-monatige randomisierte Doppelstudie zur Bewertung der Sicherheit und Wirksamkeit von Buntanetap bei Teilnehmern mit früher AD (DUET-AD)

10. November 2026 aktualisiert von: Annovis Bio Inc.

Eine 6-monatige und 18-monatige prospektive, randomisierte, placebokontrollierte, doppelblinde duale klinische Studie zur Untersuchung der Wirksamkeit und Sicherheit von Buntanetap bei der Behandlung von Teilnehmern mit früher Alzheimer-Krankheit

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are:

  • Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13?
  • Does buntanetap/Posiphen improve function as measured by ADCS-iADL?
  • What medical issues do participants have, if any, when taking buntanetap/Posiphen?

Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease.

Participants will:

  • Take buntanetap/Posiphen or a placebo every day for 18 months
  • Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18
  • Complete pre- and post-clinic visit phone calls

Studienübersicht

Status

Aktiv, nicht rekrutierend

Studientyp

Interventionell

Einschreibung (Geschätzt)

760

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Arizona
      • Chandler, Arizona, Vereinigte Staaten, 85286
        • MD First Research
      • Phoenix, Arizona, Vereinigte Staaten, 85004
        • Xenoscience
      • Scottsdale, Arizona, Vereinigte Staaten, 85258
        • Clinical Endpoints
    • California
      • Anaheim, California, Vereinigte Staaten, 92805
        • Advanced Research Center
      • Canoga Park, California, Vereinigte Staaten, 91303
        • Hope Clinical Research
      • Imperial, California, Vereinigte Staaten, 92251
        • Sun Valley Research
      • Los Angeles, California, Vereinigte Staaten, 90095
        • Mary S. Easton Center for Alzheimer's Research and Care, UCLA
      • Sacramento, California, Vereinigte Staaten, 95816
        • UC Davis Alzheimer's Disease Research Center
      • San Marcos, California, Vereinigte Staaten, 92069
        • The Neuron Clinic
    • Colorado
      • Basalt, Colorado, Vereinigte Staaten, 81621
        • Mountain Neurological Center
      • Englewood, Colorado, Vereinigte Staaten, 80113
        • CenExel Rocky Mountain
    • Connecticut
      • Norwalk, Connecticut, Vereinigte Staaten, 06851
        • Research Center for Clinical Trials
    • Florida
      • Aventura, Florida, Vereinigte Staaten, 33180
        • Visionary Investigators Network
      • Boca Raton, Florida, Vereinigte Staaten, 33487
        • SFM Clinical Research
      • Clermont, Florida, Vereinigte Staaten, 34711
        • K2 Medical Research
      • Daytona Beach, Florida, Vereinigte Staaten, 32114
        • K2 Medical Research Daytona
      • Fort Myers, Florida, Vereinigte Staaten, 33912
        • Neuropsychiatric Research Center
      • Hallandale, Florida, Vereinigte Staaten, 33009
        • Velocity Clinical
      • Jacksonville, Florida, Vereinigte Staaten, 32216
        • Jacksonville Center for Clinical Research
      • Lady Lake, Florida, Vereinigte Staaten, 32159
        • K2 Medical Research
      • Lake Worth, Florida, Vereinigte Staaten, 33462
        • Headlands Research JEM
      • Lakeland, Florida, Vereinigte Staaten, 33803
        • Accel Research Sites Lakeland (Alcanza)
      • Maitland, Florida, Vereinigte Staaten, 32751
        • K2 Medical Research
      • Melbourne, Florida, Vereinigte Staaten, 32940
        • ClinCloud Clinical Research
      • Merritt Island, Florida, Vereinigte Staaten, 32952
        • Flourish Research/Merritt Island Medical Research
      • Miami, Florida, Vereinigte Staaten, 33137
        • Miami Jewish Health
      • Naples, Florida, Vereinigte Staaten, 34102
        • Aqualane Clinical Research
      • New Port Richey, Florida, Vereinigte Staaten, 34652
        • Suncoast Clinical Research
      • Orlando, Florida, Vereinigte Staaten, 32832
        • Conquest Research
      • Tampa, Florida, Vereinigte Staaten, 33609
        • Axiom Brain Health, LLC
      • Winter Park, Florida, Vereinigte Staaten, 32789
        • Conquest Research
    • Georgia
      • Decatur, Georgia, Vereinigte Staaten, 30030
        • Accel Neurosciences
      • Gainesville, Georgia, Vereinigte Staaten, 30501
        • CARE (Center for Advanced Research & Education)
    • Hawaii
      • Honolulu, Hawaii, Vereinigte Staaten, 96817
        • Hawaii Pacific Neuroscience
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60612
        • Rush University Medical Center
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Re:Cognition Chicago
      • Chicago, Illinois, Vereinigte Staaten, 60618
        • Charter Research Chicago
      • Chicago, Illinois, Vereinigte Staaten, 60640
        • Great Lakes Clinical Trials/Flourish Research
      • Springfield, Illinois, Vereinigte Staaten, 62702
        • Southern Illinois University
    • Indiana
      • Indianaopolis, Indiana, Vereinigte Staaten, 46256
        • JWM Research
    • Kansas
      • Wichita, Kansas, Vereinigte Staaten, 37214
        • Ascension via Christi Research
    • Louisiana
      • Metairie, Louisiana, Vereinigte Staaten, 70006
        • Tandem Intermediate
    • Maryland
      • Pikesville, Maryland, Vereinigte Staaten, 21208
        • Headlands Research Pharmasite
    • Massachusetts
      • Foxborough, Massachusetts, Vereinigte Staaten, 02035
        • Neurology Center of New England, PC
      • Plymouth, Massachusetts, Vereinigte Staaten, 02360
        • Headlands Research Easter Massachusetts
      • Russells Mills, Massachusetts, Vereinigte Staaten, 02747
        • Mayflower Clinical
      • Springfield, Massachusetts, Vereinigte Staaten, 01103
        • Elixia MA
    • Michigan
      • Farmington Hills, Michigan, Vereinigte Staaten, 48334
        • Quest Research Institute
    • Mississippi
      • Flowood, Mississippi, Vereinigte Staaten, 39232
        • Precise Research Center
    • Missouri
      • Chesterfield, Missouri, Vereinigte Staaten, 63005
        • Clinical Research Professionals - Headlands Research
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89121
        • Oasis Clinical Trials LLC
    • New Jersey
      • Toms River, New Jersey, Vereinigte Staaten, 08755
        • Cenexel Advanced Medical Research of New Jersey (AMRI)
      • West Long Branch, New Jersey, Vereinigte Staaten, 07764
        • Advanced Clinical Institute
    • New York
      • Amherst, New York, Vereinigte Staaten, 14226
        • Dent Neurologic Institute
      • Brooklyn, New York, Vereinigte Staaten, 11235
        • SPRI
      • Lake Success, New York, Vereinigte Staaten, 11042
        • Neurological Associates of Long Island
      • New York, New York, Vereinigte Staaten, 10003
        • New York Neurology Associates
      • Staten Island, New York, Vereinigte Staaten, 10314
        • Richmond Behavioral Associates
      • Syracuse, New York, Vereinigte Staaten, 13210
        • Ichor Research
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27705
        • Duke University
      • Matthews, North Carolina, Vereinigte Staaten, 28105
        • AMC Research/Flourish Research
    • Ohio
      • Beavercreek, Ohio, Vereinigte Staaten, 45432
        • American Clinical Research Center
      • Centerville, Ohio, Vereinigte Staaten, 45459
        • Valley Medical Research
      • Independence, Ohio, Vereinigte Staaten, 44131
        • Insight Clinical Trials
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97210
        • Summit Headlands
    • Pennsylvania
      • Media, Pennsylvania, Vereinigte Staaten, 19063
        • Suburban Research Associates
      • Plymouth Meeting, Pennsylvania, Vereinigte Staaten, 19462
        • K2 Keystone
    • Rhode Island
      • East Providence, Rhode Island, Vereinigte Staaten, 02914
        • Rhode Island Mood and Memory Research Institute
    • South Carolina
      • Summerville, South Carolina, Vereinigte Staaten, 29486
        • Palmetto Primary Care & Specialty Physicians
    • Tennessee
      • Cordova, Tennessee, Vereinigte Staaten, 38018
        • Neurology Clinic, P.C.
      • Nashville, Tennessee, Vereinigte Staaten, 37204
        • K2 Medical Research Nashville
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78757
        • Senior Adults Specialty Research
      • Houston, Texas, Vereinigte Staaten, 77094
        • NeuroMind Clinical Trials
      • Round Rock, Texas, Vereinigte Staaten, 78681
        • Central Texas Neurology Associates
      • Wichita Falls, Texas, Vereinigte Staaten, 76309
        • Grayline Research Center
    • Vermont
      • Bennington, Vermont, Vereinigte Staaten, 05201
        • Memory Clinic, Inc.
    • Virginia
      • Arlington, Virginia, Vereinigte Staaten, 22205
        • Sana Research
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Re:Cognition Fairfax

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

55 Jahre bis 85 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Diagnosis of AD according to the 2024 National Institute on Aging and Alzheimer's Association criteria.

  2. Male or female, aged 55 - 85 years.

  3. MMSE 20-28 at screening and baseline.

  4. CDR global score=0.5 or 1, with memory box score at least 0.5 at screening and baseline.

  5. Positive for amyloid beta as defined by plasma p-tau217 level at screening.

  6. Neuroimaging (MRI) consistent with the clinical diagnosis of AD and without findings of significant exclusionary abnormalities (see exclusion criteria # 4). A historical MRI, up to 1 year prior to screening, may be used as long as there have been no interval clinical neurologic events that may suggest a change in the MRI scan.

  7. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week) and will accompany the participant on study visits at designated times.

  8. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    • Intrauterine device (IUD),

    • Intrauterine hormone-releasing system (IUS),

    • Bilateral tubal occlusion,

    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant. If not, an additional highly effective method of contraception should be used),

    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  9. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    • IUD,
    • IUS,
    • Bilateral tubal occlusion.
  10. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent. At re-consent, a legally authorized representative may co-sign if participants do not meet the general cognition and functional performance needed in the opinion of the investigator.

  11. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.

  12. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section for details on prohibited and permitted medications.

    • Cholinesterase inhibitors and/or memantine medication,
    • Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure in 3 years prior to screening
    • Mood-stabilizing psychotropic agents including, but not limited to, lithium.
  13. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  14. Participants previously exposed to buntanetap can still be included in the study after a 28-day wash out period.

Exclusion Criteria:

  1. Has a history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI), serotonin and norepinephrine reuptake inhibitors (SNRI) or other anti-depression medication (e.g. Wellbutrin) at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  2. Has non-AD dementia, such as vascular dementia, Lewy body dementia, frontotemporal disease, PD dementia, B12 and thyroid deficiency caused dementia.

  3. History of a seizure disorder, if stable on medication is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. Screening MRI (or historical MRI, if applicable) of the brain indicative of significant abnormality, including, but not limited to, prior hemorrhage (>5) or infarct > 1 cm3, > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor such as meningioma unless they are documented and stable).

  5. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women ((in the absence of a bundle branch block), or torsades de pointes.

  6. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

  7. Has uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the PI believes the participant's diabetes is under control.

  8. Has clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) <50 mL/min/BSA (body surface area) or hepatic impairment (alkaline phosphatase (ALP) > 2.0 ULN and/or total bilirubin > 2.0 ULN).

  9. Has any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT)) greater than twice the upper limit of normal will be excluded.

  10. Is at imminent risk of self-harm, based on clinical interview and responses on the C- SSRS, or of harm to others in the opinion of the PI. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to items 4 or 5 in assessment of suicidal ideation on the C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  11. Has cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  12. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.

  13. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  14. Participants with learning disability or developmental delay.

  15. Participants whom the PI deems to be otherwise ineligible.

  16. Participants with a known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified Microcrystalline Cellulose
    • Dibasic Calcium Phosphate Dihydrate
    • Mannitol
    • Stearic Acid
    • Hypromellosee (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  17. Participant is currently pregnant, breast-feeding, and/or lactating.

  18. Participant is currently taking strong and moderate CYP3A4 inhibitors and/or inducers. Refer to Concomitant Medications section below for details on prohibited and permitted medications.

  19. Participants with uncontrolled hypertension (systolic >160mm Hg and/or diastolic >95mm Hg) or hypotension (systolic <90mm Hg and/or diastolic <60 mm Hg) and deemed medically significant by the PI.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Vervierfachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Placebo-Komparator: Placebo

Placebo capsule by mouth once daily for 18 months

Experimental: buntanetap

30mg capsule by mouth once daily for 18 months

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Alzheimer's Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog13)
Zeitfenster: From screening to 6-month readout, to end of treatment at 18 months.

ADAS-Cog13 includes the original ADAS-Cog11 items that assess cognitive function across the memory, language, praxis, and orientation domains and adds a number cancellation task and a delayed free recall task. Total scores range from 0-85, with higher scores indicating greater cognitive impairment.

From screening to 6-month readout, to end of treatment at 18 months.
Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Scale (ADCS-iADL)
Zeitfenster: From screening to 6-month readout, to end of treatment at 18 months.

The Alzheimer's Disease Cooperative Study-Activities of Daily Living Scale (ADCS-ADL) is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's study partner to assess function to the degree to which the participant can perform a variety of tasks. The questionnaire asks 6 questions of basic ADLs and 17 instrumental ADLs. The iADL are more complex tasks, including activities such as shopping, maintaining appointments, or managing one's belongings or finances. The ADCS-iADL subset is assessed with items 6a and 7-23; scores range from 0 to 59, with lower scores indicating greater impairment in function.

From screening to 6-month readout, to end of treatment at 18 months.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Nützliche Links

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

4. Februar 2025

Primärer Abschluss (Geschätzt)

1. Dezember 2027

Studienabschluss (Geschätzt)

1. Juni 2028

Studienanmeldedaten

Zuerst eingereicht

26. November 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. November 2024

Zuerst gepostet (Tatsächlich)

29. November 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren